These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36917522)

  • 1. Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience.
    Gelato F; Mastorino L; Quaglino P; Cavaliere G; Ortoncelli M; Ribero S
    Dermatitis; 2023; 34(5):445-447. PubMed ID: 36917522
    [No Abstract]   [Full Text] [Related]  

  • 2. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjunctivitis in dupilumab clinical trials.
    Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
    Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
    Napolitano M; Di Guida A; Fabbrocini G; Patruno C
    Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice.
    Paganini C; Spelta S; Tofani L; Talamonti M; Bianchi L; Coassin M; Di Zazzo A; Galluzzo M
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999383
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
    Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
    Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis.
    Hayama K; Fujita H
    Dermatol Ther; 2022 Jul; 35(7):e15575. PubMed ID: 35536445
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
    Boesjes CM; Van der Gang LF; Zuithoff NPA; Bakker DS; Spekhorst LS; Haeck I; Kamsteeg M; De Graaf M; De Bruin-Weller MS
    Acta Derm Venereol; 2023 Feb; 103():adv00872. PubMed ID: 36794894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis.
    Patruno C; Potestio L; Fabbrocini G; Napolitano M
    Dermatol Ther; 2022 Dec; 35(12):e15933. PubMed ID: 36227462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Liberman P; Shifera AS; Berkenstock M
    Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
    Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K
    J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.
    Costedoat I; Wallaert M; Gaultier A; Vasseur R; Vanhaecke C; Viguier M; Cordelette C; Denoyer A; Ferrier le Bouëdec MC; Coutu A; Lamiaux M; Tran THC; Lacour JP; Elmaleh V; Tetart F; Gueudry J; Tauber M; Giordano-Labadie F; Cassagne M; Nosbaum A; Ouilhon C; Jachiet M; Tadayoni R; Dezoteux F; Staumont-Salle D; Bouleau J; Labalette P; Doan S; Soria A; Mortemousque B; Seneschal J; Barbarot S;
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1056-1063. PubMed ID: 36732052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.